Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXNQLU)

Drug Name
TM30338 Drug Info
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Discontinued in Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMXNQLU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neuropeptide Y receptor type 2 (NPY2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NEUROPEPTIDE-Y DMINQP1 N. A. N. A. Phase 2 [3]
PYY3-36 DMTGFV6 Obesity 5B81 Discontinued in Phase 2 [4]
AC-162352 DME98LV Obesity 5B81 Discontinued in Phase 1 [4]
BMS-192548 DMHAWBR Obesity 5B81 Preclinical [4]
CIN-110 DMYMZQW Obesity 5B81 Preclinical [5]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [6]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [6]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [6]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV Discovery agent N.A. Investigative [6]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Neuropeptide Y receptor type 4 (NPY4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TM30339 DMW7LQT Schizophrenia 6A20 Discontinued in Phase 2 [7]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [6]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [6]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [6]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV Discovery agent N.A. Investigative [6]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 Discovery agent N.A. Investigative [6]
Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMVWM75 Discovery agent N.A. Investigative [6]
[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMWFGBC Discovery agent N.A. Investigative [6]
[125I]GR231118 DMFWE4H Discovery agent N.A. Investigative [8]
PD-4074 DM4BDEY Diabetic complication 5A2Y Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 2 (NPY2R) TTJ6WK9 NPY2R_HUMAN Modulator [2]
Neuropeptide Y receptor type 4 (NPY4R) TTW4N16 NPY4R_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023122)
2 Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108)
3 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
4 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5 Clinical pipeline report, company report or official report of CinFina Pharma
6 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
7 Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev. 2007 Oct;28(6):664-84.
8 [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307).